155399-10-3

Basic information

• Product Name: 4-BENZYL-3-PENT-4-ENOYL-1,3-OXAZOLIDIN-2-ONE
• Synonyms: 4-BENZYL-3-PENT-4-ENOYL-1,3-OXAZOLIDIN-2-ONE;(4R)-3-(1-Oxo-4-penten-1-yl)-4-(phenylMethyl)-2-oxazolidinone;(4R)-3-(4-Pentenoyl)-4-(phenylMethyl)-1,3-oxazolidin-2-one;(R)-4-Benzyl-3-(pent-4-enoyl)oxazolidin-2-one
• CAS NO: 155399-10-3
• Molecular Formula: C₁₅H₁₇NO₃
• Molecular Weight: 259.3
• Mol File: 155399-10-3.mol
• Article Data: 24

Chemical Properties

• Appearance: /
• Solubility: Dichloromethane, Diethyl Ether, Ethyl Acetate, Methanol
• CAS DataBase Reference: 4-BENZYL-3-PENT-4-ENOYL-1,3-OXAZOLIDIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYL-3-PENT-4-ENOYL-1,3-OXAZOLIDIN-2-ONE(155399-10-3)
• EPA Substance Registry System: 4-BENZYL-3-PENT-4-ENOYL-1,3-OXAZOLIDIN-2-ONE(155399-10-3)

Safety Data

• Hazardous Substances Data: 155399-10-3(Hazardous Substances Data)

Usage

Chemical Properties

Colorless Oil

Uses

(4R)-3-(1-Oxo-4-penten-1-yl)-4-(phenylmethyl)-2-oxazolidinone (cas# 155399-10-3) is a compound useful in organic synthesis.

Upstream product

• 591-80-0 pent-4-enoic acid 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 39716-58-0 pent-4-enoyl chloride 
• 178327-16-7 C₄H₇CO₂COC₄H₉ 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 1010704-83-2 C₂₅H₂₉NO₅ 
• 1214939-83-9 C₁₉H₂₃NO₅ 
• 1166991-50-9 C₁₉H₂₃NO₅ 
• 324741-98-2 (R)-3-((2S,3S)-2-Allyl-3-hydroxy-pent-4-enoyl)-4-benzyl-oxazolidin-2-one 
• 1297139-24-2 (4R)-3-[(2S,3S,4E)-3-hydroxy-5-phenyl-2-(2-propen-1-yl)-4-pentenoyl]-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 955406-32-3 (R)-4-((R)-4-Benzyl-2-oxo-oxazolidin-3-yl)-3-(4-benzyloxy-2,6-dimethyl-benzyl)-4-oxo-butyraldehyde 
• 955373-73-6 (R)-4-((R)-4-benzyl-2-oxo-oxazolidin-3-yl)-3-(4-benzyloxy-2,6-dichloro-benzyl)-4-oxo-butyraldehyde 
• 955406-20-9 (R)-4-((R)-4-Benzyl-2-oxo-oxazolidin-3-yl)-3-(6-chloro-2,3-difluoro-4-trifluoromethyl-benzyl)-4-oxo-butyraldehyde 
• 1132653-78-1 (R)-2-((S)-2-(2-(4-chlorobenzylamino)-2-oxoethyl)pent-4-enamido)-1-phenylethyl pent-4-enoate 
• 1192277-16-9 N-((6-chloropyridin-3-yl)methyl)-2-((2R,6S,E)-5,12-dioxo-2-phenyl-1-oxa-4-azacyclododec-8-en-6-yl)acetamide 
• 1192277-45-4 N-(4-chlorobenzyl)-2-((3R,11S,E)-5,12-dioxo-3-phenyl-1-oxa-4-azacyclododec-8-en-11-yl)acetamide 
• 1192277-35-2 N-(4-chlorobenzyl)-2-((2R,6S,E)-4-methyl-5,12-dioxo-2-phenyl-1-oxa-4-azacyclododec-8-en-6-yl)acetamide 

Relevant articles and documents

Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route

Stimulator of Interferon Genes (STING) plays an important role in innate immunity by inducing type I interferon production upon infection with intracellular pathogens. STING activation can promote increased T-cell activation and inflammation in the tumor microenvironment, resulting in antitumor immunity. Natural and synthetic cyclic dinucleotides (CDNs) are known to activate STING, and several synthetic CDN molecules are being investigated in the clinic using an intratumoral administration route. Here, we describe the identification of STING agonist 15a, a cyclic dinucleotide structurally diversified from natural ligands with optimized properties for systemic intravenous (iv) administration. Our studies have shown that STING activation by 15a leads to an acute innate immune response as measured by cytokine secretion and adaptive immune response via activation of CD8+ cytotoxic T-cells, which ultimately provides robust antitumor efficacy.

STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING

The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

Structural requirements of histone deacetylase inhibitors: C4-modified saha analogs display dual HDAC6/HDAC8 selectivity

A compound having formula I for histone deacetylase inhibition is provided: or a pharmaceutically acceptable salt or hydrate thereof wherein R is alkyl, C6-18 aryl, C5-18 heteroaryl, C8-22 alkylaryl, C8-22 alkyl